The goal of the Microarray Shared Facility is to provide comprehensive, state-of-the-art genomic analysis technologies to Cancer Center investigators. In accomplish this, the Microarray Shared Facility (MSF) provides whole genome and targeted gene expression analysis, high- and low-throughput whole genome and custom genotyping, whole genome methylation analysis, and targeted sequencing analysis to Cancer Center members and university investigators at large. The MSF was formerly the Gene Expression Shared Facility, and has both focused it's mission and extended access to core technologies related to the largescale analysis of gene expression. The facility has recently been expanded to include the iScan and BeadXpress systems from lllumina in order to complement the existing Affymetrix GeneChip system, which is comprised of the Affymetrix 3000 7G scanner with an autoloader, two FS450 fluidics stations and two Hyb 640 hybridization ovens. Because changes in technology can complicate comparison to previous studies, the MSF facility has the capacity to perform whole genome genotyping, copy number variation analysis, and gene expression microarrays on multiple systems in order to accommodate the needs of Cancer Center investigators who may have committed to working with one platform or another. In addition, we can perform microRNA profiling and whole genome methylation profiling using a Chromatin-IP protocol followed by hybridization on the human or mouse promoter chip (ChlP-Chip). The addition of the new platforms will provide Cancer Center members and university researchers several options when considering experimental design and data analysis. Together, our research team and laboratory resources will provide the necessary expertise and cutting-edge technology to support the proposed molecular studies described in this Comprehensive Cancer Center proposal.
The ability to analyze changes in gene and in gene expression rapidly is critical in order to understand the differences between cancer cells and normal tissue, and even among different cancer types that affect the same tissues (e.g. the many forms of breast or lung cancer). Genomic analysis is important in identifying genomic events associated with tumor initiation or progression, defining tumor types, and predicting response to therapies.
|Carson, Tiffany L; Hardy, Claudia M; Greene, Eva et al. (2014) Considerations for bio-specimen collection among black women residing in the rural Deep South participating in a cancer prevention study. J Community Genet 5:257-63|
|Fauci, Janelle M; Sabbatino, Francesco; Wang, Yangyang et al. (2014) Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132:203-10|
|Devine, D J; Rostas, J W; Metge, B J et al. (2014) Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-*/SMAD signaling. Oncogene 33:2620-8|
|Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94|
|Saini, Reshu; Hoyt, Kenneth (2014) Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis. Imaging Med 6:41-52|
|Sonpavde, Guru; Willey, Christopher D; Sudarshan, Sunil (2014) Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 23:305-15|
|Shim, Eun-Hee; Livi, Carolina B; Rakheja, Dinesh et al. (2014) L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 4:1290-8|
|Gan, Yujun; Buckels, Ashiya; Liu, Ying et al. (2014) Human GH receptor-IGF-1 receptor interaction: implications for GH signaling. Mol Endocrinol 28:1841-54|
|Johnson, David H; Wilson, W William; DeLucas, Lawrence J (2014) Protein solubilization: a novel approach. J Chromatogr B Analyt Technol Biomed Life Sci 971:99-106|
|Ramos, Theresa N; Bullard, Daniel C; Barnum, Scott R (2014) ICAM-1: isoforms and phenotypes. J Immunol 192:4469-74|
Showing the most recent 10 out of 364 publications